The effects of prostaglandin E1 on interleukin-6, pulmonary function and
postoperative recovery in oesophagectomised patients.
Author(s): Farrokhnia E, Makarem J, Khan ZH, Mohagheghi M, Maghsoudlou M, Abdollahi A.
Affiliation(s): The Cancer Institute, Imam Khomeini Medical Center, Tehran University, School of
Medicine, Tehran, Iran.
Publication date & source: 2009, Anaesth Intensive Care. , 37(6):937-43
The inflammatory reactions and tissue response after oesophagectomy are leading
causes of postoperative morbidity and mortality. We evaluated the effects of
intraoperative infusion of prostaglandin E1 (PGE1) on interleukin-6 (IL-6)
levels, (A-a) DO2, pulmonary function and complications. This randomised
double-blind clinical trial study was performed on patients undergoing
transthoracic oesophagectomy due to cancer Thirty patients were randomly
allocated to two groups: the PGE1 group (infusion of PGE1 20 ng kg(-1) min(-1))
and a placebo group (infusion of normal saline 0.9%). The infusion was started
before induction of anaesthesia and continued until the end of the operation. The
groups were comparable in basic characteristics and preoperative pulmonary
function. Patients in the PGE1 group were discharged significantly earlier from
the intensive care unit (72+/-9 vs 83+/-17 hours) and hospital (13+/-4 vs 18+/-8
days) (P=0.04 and 0.03, respectively). The (A-a) DO2 was significantly less in
the PGE1 group at 12 and 24 hours after the operation (P=0.001, P=0.003,
respectively). Postoperatively, IL-6 levels were significantly higher in the
placebo group than in the PGE1 group. There were no differences in the forced
expiratory volume in the first second or forced vital capacity. The findings
indicate that infusion of PGE1 attenuates the increase in serum levels of IL-6 in
patients undergoing esophagectomy and improves the (A-a) DO2. Stays in the
intensive care unit and hospital were shorter in the PGE1 group. However, there
were no differences in pulmonary complications.
|